Short Interest in Immuron (NASDAQ:IMRN) Increases By 109.7%

Immuron (NASDAQ:IMRN) saw a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling 11,600 shares, an increase of 109.7% from the March 31st total of 5,532 shares. Currently, 0.2% of the shares of the company are sold short. Based on an average daily trading volume, of 20,437 shares, the short-interest ratio is presently 0.6 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Immuron stock. Citadel Advisors LLC purchased a new stake in Immuron (NASDAQ:IMRN) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 19,562 shares of the company’s stock, valued at approximately $37,000. Citadel Advisors LLC owned approximately 0.29% of Immuron as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 0.12% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Immuron in a research note on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Immuron currently has an average rating of “Sell”.

Immuron Price Performance

Shares of NASDAQ IMRN traded up $0.01 during mid-day trading on Friday, reaching $0.89. 14,549 shares of the company traded hands, compared to its average volume of 31,927. Immuron has a fifty-two week low of $0.68 and a fifty-two week high of $2.39. The stock has a fifty day simple moving average of $0.80 and a 200-day simple moving average of $1.16.

Immuron (NASDAQ:IMRN) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.10) EPS for the quarter. The company had revenue of $1.40 million for the quarter.

Immuron Company Profile

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections.